Table 3.
Associations between treatments and mutations in ER + /HER2-cohort
| Treatment | All patients (113) | ESR1 mutant (34) | ESR1 WT (79) | p-values | PIK3CA mutant (36) | PIK3CA WT (77) | p-values |
|---|---|---|---|---|---|---|---|
| Neo/adj chemotherapy | |||||||
| Yes | 68 (60.2%) | 24 (70.6%) | 44 (55.7%) | 0.15 | 20 (55.6%) | 48 (62.3%) | 0.54 |
| No | 45 (39.8%) | 10 (29.4%) | 35 (44.3%) | 16 (44.4%) | 29 (37.7%) | ||
| Chemotherapy in metastatic disease | |||||||
| Yes | 61 (54.0%) | 23 (67.6%) | 38 (48.1%) | 0.067 | 19 (52.8%) | 42 (54.5%) | 1.00 |
| No | 52 (46.0%) | 11 (32.4%) | 41 (51.9%) | 17 (47.2%) | 35 (45.5%) | ||
| Palbociclib | |||||||
| Yes | 23 (20.4%) | 2 (5.9%) | 21 (26.6%) | 0.011 | 5 (13.9%) | 18 (23.4%) | 0.32 |
| No | 90 (79.6%) | 32 (94.1%) | 58 (73.4%) | 31 (86.1%) | 59 (76.6%) | ||
| Everolimus | |||||||
| Yes | 16 (14.2%) | 7 (20.6%) | 9 (11.4%) | 0.24 | 4 (11.1%) | 12 (15.6%) | 0.77 |
| No | 97 (85.8%) | 27 (79.4%) | 70 (88.6%) | 32 (88.9%) | 65 (84.4%) | ||